StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Koselugo (selumetinib) — US product sales by Quarter

Koselugo (selumetinib) — US product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Koselugo (selumetinib) — US product sales: $52M in Q2 2026, unchanged from a year earlier.

Latest, Q2 2026
52
Period ended Jun 30, 2026
Change on a year earlier
0.0%
52 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Koselugo | 177 | | 29 | | 27 | | 52 | | - | | 54 | | 51 | | 45 | | 50 | | 34 | | 27 | | 21 | | 78 | | 90”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedKoselugo (selumetinib) — US product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026520.0%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202642-20.8%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202562+10.7%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202551-7.3%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202552-5.5%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202553+15.2%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202456+9.8%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202455+1.9%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202455+14.6%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202446+12.2%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202351+6.3%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202354+50.0%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 202348+2.1%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202341+36.7%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202248+50.0%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202236+44.0%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up koselugo (selumetinib) — US product sales

Cite this data

StockData. (2026). AstraZeneca Koselugo (selumetinib) — US product sales ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-koselugo-us

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.